Chlorpyrifos (O,O-diethyl-O-(3,5,6-trich]oro-2-pyridyl)-phosphorothioate), an organophosphate insecticide, was evaluated for its potential to produce developmental and reproductive toxicity in rats following oral exposure. Pregnant Fischer 344 rats were given doses of 0 (com oil vehicle), 0.1, 3.0, or 15 mg chlorpyrifos/kg/day, by gavage, on Gestation Days 6 through 15. Maternal effects noted at the two higher dose levels included decreased cholinesterase levels at 3.0 mg/kg/day and cholinergic signs (excessive salivation and tremors), decreased cholinesterase levels, and decreased body weight gain at 15 mg/kg/day. No maternal effects were apparent at 0.1 mg/kg/day. Although maternal toxicity was observed at these two higher exposure levels, no developmental effects were noted at any dose. In a two-generation reproduction study, Sprague-Dawley rats were maintained on diets supplying 0, 0.1,1.0, or 5.0 mg chlorpyrifos/kg/day. Parental effects included decreased plasma and erythrocyte cholinesterase at 1.0 mg/kg/day, and decreased plasma, erythrocyte, and brain cholinesterase and histopathologic alterations of the adrenal zona fasciculata at 5.0 mg/kg/day. The histopathologic alterations of the adrenal were characterized as very slight to slight vacuolation (consistent with fatty change) in males, and very slight vacuolation and/or altered tinctorial properties in females. No effects on the reproductive or fertility indices or on the histopathology of reproductive tissues were observed at any dose level, and no neonatal effects were observed at 0.1 or 1.0 mg/kg/ day in the Fl or F2 litters. Parental toxicity at the high dose was accompanied by decreased pup body weight and increased pup mortality in the Fl litters only. These data show that oral administration of chlorpyrifos to rats at parentally toxic dose levels was not embryolethal, embryo/fetotoxic, or teratogenic and did not adversely affect fertility or the function or structure of the reproductive organs. Although effects on neonatal growth and survival were observed at a maternally toxic dose level in one generation, this effect was not observed in the subsequent generation and, therefore, may not have been related to treatment o 19% soda? of Tmtkoiogy Chlorpyrifos (O,O-diethyl-O-(3,5,6-trichloro-2-pyridyl)-phosphorothioate) is an organophosphate insecticide that ex-1 To whom correspondence should be addressed.
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hibits a broad spectrum of activity against arthropod pests of plants, animals, and humans, and has wide applications in both agricultural and commercial pest control. As with other organophosphate insecticides, the principle mechanism of action of chlorpyrifos is the phosphorylation and subsequent inactivation of acetylcholinesterase. The current threshold limit value for chlorpyrifos is 200 /xg/m 3 and is based on the no-observed-effect level (30 /zg/kg/day) in humans following repeated exposures (ACGIH, 1991) .
Extensive oral toxicological testing of chlorpyrifos has been conducted. The acute oral toxicity of chlorpyrifos is moderate, with oral LD50 values ranging from 118 to 245 mg/kg for rats, greater than 1000 mg/kg for rabbits, and approximately 504 mg/kg for guinea pigs (McCollister et al., 1974) . Inhibition of cholinesterase enzymes was the primary manifestation of toxicity in subchronic and chronic dietary toxicity studies with chlorpyrifos in rats and dogs (McCollister et al., 1974) . Dietary exposure to 0.1 mg/kg/day or less of chlorpyrifos for 2 years produced no significant effects in either species, whereas plasma and erythrocyte cholinesterase levels were decreased in rats or dogs at 1.0 mg/kg/ day. A reversible inhibition of plasma, erythrocyte, and brain cholinesterase activity was the only effect observed at the highest dose tested (3.0 mg/kg/day) in both rats and dogs. A recently conducted 2-year dietary toxicity and oncogenicity study in Fischer 344 rats confirmed the previous chronic noobserved-effect level (NOEL) of 0.1 mg/kg/day and reported decreased plasma and erythrocyte cholinesterase at 1.0 mg/ kg/day, and decreased cholinesterase, decreased body weight, and altered weight and histology of the adrenal gland at a high dose of 10 mg/kg/day (Young et al., 1990) . No evidence of oncogenicity was observed in any of the chronic assays at any exposure level.
In an oral developmental toxicity study reported by Deacon et al. (1980) , CF-1 mice given a high dose of 25 mg/ kg/day, by gavage, on Days 6 through 15 of gestation showed severe maternal toxicity as exhibited by mortality, clinical signs of a cholinergic response, decreased cholinesterase levels, and decreased body weight. Less severe, dose-related evidence of maternal toxicity was observed at dose levels of 10 and 1.0 mg/kg/day. The maternal NOEL was 0.1 mg/ kg/day, based on the lack of plasma cholinesterase inhibition. Although chlorpyrifos produced maternal effects at doses 3= 1.0 mg/kg/day, no developmental toxicity was observed at doses up to and including 10 mg/kg/day and chlorpyrifos was not embryolethal or teratogenic at any of the dose levels tested. The only adverse developmental effects noted were decreased fetal body weight and delayed skeletal ossification of the skull and stemebrae at 25 mg/kg/day. The developmental effects at the high exposure level could not be dissociated from the severe maternal toxicity observed in the highdose dams.
The two studies reported herein were conducted to further evaluate the developmental toxicity of chlorpyrifos in a second species and to assess the potential reproductive toxicity of chlorpyrifos following oral exposure. The oral route of exposure was selected for both studies since it is a likely route of potential human exposure and has been shown to be well absorbed in animals and humans when given by this route.
MATERIALS AND METHODS

Test Material
Two lots of chlorpyrifos (technical grade Dursban 2 F insecticide) were obtained from The Dow Chemical Company (Midland. MI). The purity of the test material was determined by liquid and gas chromatography to be 96.6% (Lot AGR 190183; teratology study) or 98.5% (Lot AGR 273801; reproduction study) chlorpyrifos. Periodic reanalyses of the test material from Lot AGR 273801 confirmed its stability over the duration of the reproduction study. The structure of chlorpyrifos is shown in Fig. 1 .
Test Species and Husbandry
Male and female Fischer 344 rats, 3 approximately 10 weeks of age, were obtained for the developmental toxicity study; Sprague-Dawley rats, 4 approximately 4 weeks of age, were obtained for the reproduction study. Due to declining fertility observed in Fischer 344 rats in long-term studies, the Sprague-Dawley rats were used in the reproduction study. All rats were examined for health status by the laboratory veterinarian and acclimated to the laboratory 3 environment for 2 weeks prior to use. All rats were identified by uniquely numbered metal ear tags. Rats were housed singly in wire-mesh, stainless-steel cages, suspended in racks provided with cage board to minimize odor and aid in maintaining a clean environment. During the gestation and lactation phases of the reproduction study, females were housed in plastic cages containing ground corn cob nesting material. The animal rooms of the facility were designed to maintain temperature at 22°C, relative humidity at approximately 50%, air flow at 12 exchanges per hour and a 12-hr light: 12-hr dark photoperiod. Purina Certified Rodent Chow No. 5002 6 and tap water were available ad libitum throughout the study.
Developmental Toxicity Study
Experimental design. Adult virgin female Fischer 344 rats, approximately 12 weeks of age and 175-220 g, were bred to adult males (one female to one male) from the same strain. The day sperm were found in a vaginal smear was considered Day 0 of gestation. Bred females were randomly assigned to treatment groups using computer-generated tables of random numbers. Groups of 31 to 33 bred rats were given chlorpyrifos by gavage on Days 6 through 15 of gestation at dose levels of 0 (corn oil vehicle), 0.1, 3.0, and 15 mg chlorpyrifos/kg/day. Test solutions were prepared by dissolving the test material in corn oil such that a dose volume of 4 ml/kg of body weight/day yielded the appropriate dose level. The concentrations of test material in the dose solutions ranged from 95 to 99% of the targeted concentrations and were stable in corn oil for a minimum of 28 days.
Maternal observations. Animals were observed daily throughout the experimental period for indications of toxicity. Body weights were recorded on Gestation Days 6 through 16 and on Day 21 of gestation. Feed and water consumption were recorded for each rat at 3-day intervals starting on Day 6 of gestation. Statistical analysis of body weight and body weight gain was performed using data recorded on Days 6, 9, 12, 16, and 21 of gestation. Maternal liver weight was recorded at the time of cesarean section on Day 21 of gestation. Separate groups of 10 bred rats/dose level were dosed on Days 6 through 15 of gestation and euthanized following methoxyflurane anesthesia on Day 15 of gestation (approximately 4 hr after dosing). Maternal blood was obtained from this subgroup of animals by cardiac puncture for determination of plasma and erythrocyte cholinesterase levels using a photometric technique 7 Fetal observations. Test animals were euthanized by carbon dioxide inhalation on Day 21 of gestation. The uterine horns were exteriorized through a midline abdominal incision. The following data were recorded: number and position of fetuses in utero, number of live and dead fetuses, number and position of resorption sites, number of corpora lutea, fetal sex, body weight, and crown-rump length, and gross external fetal alterations. The uteri of apparently nonpregnant animals were stained with a \Q% solution of sodium sulfide (Kopf el al., 1964) and examined for evidence of implantation sites. This procedure was done solely to determine the incidence of pregnancy and resorptions. Implantations identified with stain in apparently nonpregnant animals were not used in resorption rate calculations. One-half of each litter, selected using a table of random numbers, was examined immediately by dissection under a low-power microscope for evidence of soft tissue alterations (Staples, 1974) . The heads of rat fetuses examined by dissection were removed, placed in Bouin's fixative, and examined by the serial sectioning technique of Wilson (1965) . All fetuses were then preserved in 95% ethanol, eviscerated, and subsequently cleared and stained with Alizarin Red S (Dawson, 1926) , and examined for skeletal alterations.
Reproduction Study
Experimental design. Male and female Sprague-Dawley rats were weighed and assigned to treatment groups using a stratified, by weight. randomization procedure. Groups of 30 male and 30 female first parental (PI) generation rats were administered diets containing sufficient chlorpyrlfos to provide dose levels of 0, 0.1, 1.0, or 5.0 mg chlorpyrifos/kg/day. The dose levels were selected on the basis of a previous study (unpublished data) in which rats given diets that provided a dose of 5.0 mg chlorpyrifos/ kg/day exhibited significant depressions in brain, plasma, and erythrocyte cholinesterase. Significant depression of brain cholinesterase is considered to be a toxic response and meets the criteria for a maximum-tolerated dose. The middle-and low-dose levels were selected to establish a dose response for cholinesterase depression and a NOEL, respectively. Exposure to the treated diets was continuous throughout the duration of the study. The concentrations of chlorpynfos in the diets were adjusted weekly, based on the weekly body weights and feed consumption data, in order to maintain the targeted dose levels on a mg/kg/day basis. The concentrations of the test material in the diets ranged from 93 to 100% of the targeted concentrations and were stable in the diet for a minimum of 51 days. The treatment of the PI rats began at approximately 6 weeks of age. After approximately 10 weeks on test diets, PI rats were mated to produce the first filial generation (Fl) litters. Following weaning (3 weeks of age) of the Fl litters, 30 males and 30 females from each treatment group were randomly selected and assigned to the respective treatment group to become the second parental (P2) generation. After approximately 12 weeks of treatment following weaning of the last Fl litter, the P2 adults were bred to produce the second filial generation (F2) litters.
Breeding procedure. Each breeding program consisted of three 7-day cohabitation periods with one female and one male of the respective treatment group. For the P2 mating, cohabitation of male and female litter mates was avoided. During each breeding period, daily vaginal lavage samples were evaluated for the presence of sperm as an indication of mating. The day on which sperm were detected was considered Day 0 of gestation. Sperm-positive females were separated and placed in nesting cages. Females which failed to mate during the first 7-day mating period were placed with an alternate male from the same treatment group for the second 7-day period; the same procedure was followed for the third 7-day mating period.
Parental data. Each rat in the study was observed at least daily for evidence of treatment-related alterations in behavior or demeanor. Adult rats found dead or in moribund condition were submitted for a gross pathologic examination. All pups found dead during the lactation phase were examined grossly (externally and internally) to the extent possible and discarded. Body weights and feed consumption were recorded at least weekly throughout the study except during the cohabitation periods, at which time feed consumption was not determined.
Plasma, red blood cell (erythrocyte), and brain cholinesterase determinations were conducted on the first 10 PI and P2 adult rats/sex/dose during the scheduled necropsy. Following anesthesia with methoxyflurane, blood samples were collected from the orbital sinus for plasma and erythrocyte cholinesterase determinations. After collection of the blood samples, the anesthetized rats were euthanized by decapitation, the brains were removed, and one-half of each brain was used for cholinesterase measurements. Cholinesterase concentrations were determined using a photometric technique (see footnote 7).
Litter data. All litters were examined as soon as possible after delivery. The following parameters were recorded on each litter: litter size on the day of parturition (Day 0), the number of live and dead pups on Days 0, I, 4, 7, 14, and 21 postpartum, and the sex and weight of each pup on Days I, 4 (before and after culling), 7, 14, and 21 of lactation. Visible physical abnormalities or demeanor changes in the neonates were recorded during the lactation period.
To reduce variation in pup growth, the Fl and F2 litters which had a total number of pups exceeding 8 were culled on Day 4 postpartum. Culled litters were reduced to a total of 8 pups, 4 males and 4 females, when possible. All pups which were culled were euthanized by T61 1 injection 1 American Hoechst Corp., Somerville, NJ.
and given an external and internal gross examination. Weaning of all litters was done 3 weeks after delivery. All weanlings not held for the next generation adult animals or selected for necropsy were examined grossly and euthanized.
Gross necropsy and histopathology of adult rats. A complete necropsy was conducted by a veterinary pathologist on all PI and P2 adults following 19 and 21 weeks of exposure, respectively. The PI and P2 animals were 25 and 27 weeks of age, respectively, at the time of necropsy. The adults were fasted overnight, weighed, anesthetized with methoxyflurane, and euthanized by decapitation. The eyes were examined in situ by gently pressing a glass slide against the comea and observing the eyes under fluorescent light. An extensive list of tissues was collected and preserved in neutral, phosphate-buffered 10% formalin. The testes of 10 P2 control and high dose males were also preserved in Bouin's fixative. The lungs were infused with formalin to their approximate normal inspiratory volume. The nasal cavity was flushed with formalin via the pharyngeal duct to ensure rapid fixation of the tissue. Histologic examination of potential target organs (adrenals, brain, and gross lesions) and reproductive tissues (cervix, coagulating glands, epididymides, ovaries, oviducts, pituitary, prostate, seminal vesicles, testes, uterus, and vagina) was performed on the control and highdose groups. In addition, the livers of 10 control and high-dose P2 adult males were examined microscopically. Examination of tissues from the low and middle groups was limited to the adrenals which demonstrated treatment-related histologic changes in the high-dose group, and to gross lesions Reproductive organs were not weighed in this study as previous subchronic and chronic toxicity studies in rats failed to produce treatment-related weight changes or histopathologic alterations in these tissues (Young el al., 1990) . To substantiate the lack of treatment-related effects on selected organ weights following exposure to chlorpyrifos, the organ weight data from the chlorpyrifos 13-week dietary toxicity study in rats are presented in Table 1 .
Weanling rats. At the time of weaning, 10 pups/sex/dose level from the Fl and F2 litters were randomly selected for a complete necropsy by a veterinary pathologist. The pups were anesthetized with methoxyflurane and euthanized by decapitation. Gross pathologic examination was performed as described above for adults, except that terminal body weights were not recorded. Histologic examination of tissues was not performed.
Statistical evaluation. Body weights, body weight gains, absolute and relative organ weights, and plasma, erythrocyte, and brain cholinesterase levels were evaluated by Bartlett's test for equality of variances (Winer, 1971) . Based upon the outcome of Bartlett's test, either a parametric (Steel and Tome, I960) or nonparametric (Hollander and Wolfe, 1973) analysis of variance (ANOVA) was performed. If the ANOVA was significant, a Dunnett's test (Winer, 1971) or the Wilcoxon rank-sum test (Hollander and Wolfe, 1973 ) with Bonferroni's correction (Miller, 1966) was performed.
Descriptive statistics (means and standard deviations) were reported for feed consumption. Statistical outliers were identified by the method of Grubbs (1969) and excluded from calculations only for feed consumption. Gestation length, average time to mating, and litter size were analyzed using a nonparametric ANOVA. If the ANOVA was significant, the Wilcoxon rank-sum test with Bonferroni's correction was performed. The pregnancy rate and fertility indices were analyzed by the Fisher exact probability test (Siegel, 1956) . Evaluation of the neonatal sex ratio was performed by the binomial distribution test (Steel and Tome, 1960) . The frequency of preimplantation loss, resorptions, fetal alterations, and neonatal mortality were analyzed using the litter as the experimental unit by a censored Wilcoxon test (Haseman and Hoel, 1974 ) with Bonferroni's correction.
The nature of these studies results in the statistical evaluation of numerous parameters in the same group of animals. Thus, these data are correlated to an unknown degree (i.e., lack of independence) which severely confounds the ability to define Type I or II error (Mattsson and Park, 1983; Benignus and Muller, 1983) . The statistical tests were conducted using a nominal a = 0.05, and data meeting this criterion were identified in the tables and figures. However, it must be recognized that these statistics are descriptive in nature and without an identifiable probability level.
RESULTS
Developmental Toxicity Study
Maternal observations. All animals survived until their scheduled necropsy. Clinical signs of maternal toxicity, including excessive salivation, urine staining in the perineal region, porphyrin deposits about the eyes, vaginal bleeding, and tremors, were noted during the dosing period among animals in the 15 mg/kg/day dose group. No effects were noted on the general appearance or demeanor of animals in the control, 0.1 or 3.0 mg/kg/day dose groups.
No appreciable changes in feed consumption were noted among any of the dose groups (data not presented). However, rats among the 15 mg/kg/day dose group consumed less water initially during the dosing period than did control rats (data not presented).
Overall, the high-dose rats also gained less weight during the test period than did the control rats (Table 2) . Statistically significant decreases were noted in body weights on Days 12 and 16 and body weight gain on Days 9 through 11. Body weights at 0.1 and 3.0 mg/kg/day levels were comparable to controls throughout the study.
Data collected from groups of 10 bred rats/dose level that were necropsied on Day 15 of gestation indicated that cholinesterase levels in the plasma and erythrocytes were significantly decreased among rats given 3 or 15 mg/kg/day (Table 2) . Plasma cholinesterase levels from the 3 and 15 mg/kg/day dose groups were only 11 and 3%, respectively, of the plasma cholinesterase levels in the control animals. Erythrocyte cholinesterase levels of animals in the 3 and 15 mg/kg/day dose groups were 26 and 21%, respectively, of the control group mean. No effect on plasma or erythrocyte cholinesterase levels was observed among rats receiving 0.1 mg/kg/day of chlorpyrifos. Although brain cholinesterase levels were not evaluated in this teratology study, they were likely decreased at the high dose of 15 mg/kg/day, since they were reduced in previous studies (McCollister et al., 1974; Young et al., 1990) and in the reproduction study reported herein following repeated oral exposure of rats to dose levels of >3 mg/kg/day. No significant effect on the weight of the liver was observed at any dose level (Table 2) .
Embryo-or fetotoxicity.
Reproductive parameters and fetal body weight and crown-rump length values are presented in Table 3 . No effects on the pregnancy rate, number of implantations, preimplantation loss, resorptions, number of dead fetuses, litter size, or fetal body weight, crownrump length, or sex ratio were observed among any of the treatment groups. The increased fetal body weight observed at 3 and 15 mg/kg/day were not considered treatment-related as a dose-response was not observed for this parameter. The fetal weights at 3 and 15 mg/kg/day were also within the range of our historical control data. Grams, mean + SD. * Grams, organ weight/100 g body weight, mean i SD. c International unit/ml, mean ± SD. Determined on Gestation Day 15.
• Different from the control value by Dunnett's test, a = 0.05.
Fetal alterations.
No treatment-related effects on fetal malformations or variations were observed at any exposure level (Table 4) . Several malformations were observed scattered throughout the dose levels at incidences consistent with the historical background observed in this laboratory. Microphthalmia (small eye) was observed in one fetus in the control group, in one fetus in the 3.0 mg/kg group and in two fetuses in the 15 mg/kg dose group. Anophthalmia (eye absent) was observed in one fetus from the control group and in one fetus from the 3.0 mg/kg dose group. One fetus from the 0.1 mg/kg dose group exhibited fused ribs. A single case of cleft palate (soft-palate) was observed in a fetus from the 15 mg/kg dose group. Three fetuses from a single litter in the 15 mg/kg/day dose group exhibited dilated renal pelvis.
Minor variations in fetal morphology observed also appeared to be randomly distributed throughout the dose groups and included patent ductus arteriosus (one control fetus), hemorrhage in the liver (one fetus at 0.1 mg/kg), convoluted ureter (one fetus at 0.1 mg/kg and two fetuses at 15 mg/kg group), extra site of ossification near the sternebrae (one control fetus), and lumbar spurs (2 control fetuses, 4 fetuses at 0.1 mg/kg, 2 fetuses at 15 mg/kg). The degree of skeletal ossification was also similar across all dose groups.
Reproduction Study
Clinical observations. No treatment-related effects on behavior or demeanor were observed in males or females at any dose level during the exposure period. One PI control male was found dead on test Day 125, 7 days prior to the scheduled necropsy. No remarkable clinical observations were recorded for this rat prior to its death. Upon gross pathologic examination this animal was found to have perineal soiling, blood around the muzzle, and general visceral congestion; however, the cause of death could not be determined. One P2 male from the 0.1 mg/kg/day dose group was found dead on test Day 66, prior to the completion of the prebreeding period. The cause of death of this animal was attributed to renal and bladder calculi.
Feed consumption. No significant treatment-related effects on feed consumption were observed at any dose level in PI or P2 males or females throughout the entire study (data not presented). The feed consumption of dams given 5.0 mg chlorpyrifos/kg/day was, however, decreased slightly during the last 2 weeks of lactation.
Body weights. No significant treatment-related effects on body weights were observed in PI or P2 males or females at any dose level throughout the entire study (data not presented). The body weights of P2 males in the 5.0 mg/kg/ day dose group were, however, slightly decreased (not statistically significant) throughout the test period when compared with the control group. The lower body weights of P2 males in the high-dose group were consistent with the significantly lower weights of these animals as pups during lactation (Ta- Two animals were removed from the study dunng dosing (one exhibited glaucoma, one was inadvertently deprived of water overnight). * Number of femaJes detected as being pregnant by visual inspection of the uterus or by sodium sulfide stain/tota] number of females. c Mean ± SD. d Percentage per litter, mean ± SD. ' Mean of litter means ± SD. * Indicates statistical difference from control, a = 0 05. ble 5). When body weight gain was evaluated, PI females from the 5.0 mg/kg/day dose group also gained slightly less weight (statistically significant) during the lactation day interval 1 through 21 (data not presented). This decrease in body weight gain was attributed to the combined stress of chlorpyrifos exposure and lactation, and was consistent with the slight decreases in feed consumption observed in highdose dams during the last 2 weeks of lactation.
Cholinesterase. Dose-related statistically significant decreases in plasma and erythrocyte cholinesterase were observed in PI and P2 males and females in the 1.0 and 5.0 mg/kg/day dose groups (Fig. 2) . Plasma cholinesterase was decreased to 56-57% (males) or 41 -51% (females) of the control value at 1.0 mg/kg/day and 37-39% (males) or 28-33% (female) of the control value at 5.0 mg/kg/day. Erythrocyte cholinesterase was decreased to 31 -35% (male) or 33% (female) of the control value at 1.0 mg/kg/day and 30% (male) or 25-29% (female) of the control value at 5.0 mg/ kg/day. Statistically significant decreases in brain cholinesterase were also observed in PI and P2 males and females in the 5.0 mg/kg/day dose group. Brain cholinesterase values in males and females from the 5.0 mg/kg/day dose groups were decreased to *=52% of the control values. The statistically significant decrease in erythrocyte cholinesterase observed in P2 males at 0.1 mg/kg/day was considered spurious due to the lack of effect on this parameter in either PI males or females given 0.1 mg/kg/day or in P2 females given 0.1 mg/kg/day. A dose of 0.1 mg/kg/day has also been shown to be the no-observed-effect-level for erythrocyte cholinesterase in subchronic and chronic rat dietary toxicity studies (McCollister ef ai, 1974; Young el ai, 1990) . No significant effect on brain cholinesterase was observed in males or females in the 0.1 or 1.0 mg/kg/day dose groups.
Pup observations and body weight. No treatment-related clinical observations were observed in pups from any dose group. The body weights of male and female Fl pups from the 5.0 mg/kg/day dose group were slightly decreased on Day 1 of lactation and statistically decreased on Days 4, 7, 14 and 21 of lactation (Table 5 ). The decreased pup weights at the high dose were consistent throughout the lactation period and were accompanied by decreased survival and lower body weight gain of dams in this dose group during lactation. The decreased pup weights occurred only at a dose level that produced parental toxicity (significantly decreased brain cholinesterase and histopathologic alterations of the adrenal zona fasciculata). The body weights of male and female F2 pups from the 5.0 mg/kg/day dose group were slightly, but not statistically, decreased from lactation Days 
278 (29) 147 (29) 278 (29) 129 (29) 0.4 (1) (4) 44 (103) 89 (23) 0 0 230 (24) 124 (24) 230 (24) 106 (22) (number affected) 0.4 (1) 4 (1) 04 (1) (26) 130 (26) 244 (26) 115 (25) 0.8 (2) 8 (2) Reproductive indices, litter size, and pup survival and sex ratio. No treatment-related effects were observed on the PI or P2 male or female fertility indices, length of gestation, time to mating, pup sex ratio, or litter size in any dose group (Table 6 ). The statistically identified decreases in the PI female conception and fertility index observed in the 0.1 mg/kg/day dose group were considered spurious in view of the lack of effects on these parameters at 1.0 or 5.0 mg/kg/ day. Pup survival in the Fl litters, however, was statistically decreased on Days 14 and 21 of lactation in the 5.0 mg/kg/ day dose group. No significant effects on Fl pup survival were observed at earlier time points in the 5.0 or in the 1.0 or 0.1 mg/kg/day dose groups at any time during lactation. Importantly, the decrease in Fl pup survival observed at 5.0 mg/kg/day occurred only at a dose level that produced parental toxicity (significant decreases in brain cholinesterase and histopathologic alterations of the adrenal zona fasciculata).
Pup survival in the F2 control and 5.0 mg/kg/day litters was lower than expected. The decreased pup survival in 6.5 ± 0.6" 6.2 ± 0.6 8.5 ± 1.1 8.1 ± I.I 48.4 ±40 46.1 ± 3.7
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.9 ± 07 8.6 ± 1.5 82 ± 1.2 45.1 ± 6.1 42.7 ± 5.1 test, a = 0.05 Dose 0.1 litters 6.4 ± 0.7 6.0 ± 0.7 8.7 ± 1.0 8.2 ± 1.1 49.1 ± 4.6 46.9 ± 5.5 litters 6.6 ± 0 7 6.1 ± 0.6 9.0 ± 1.4 8.6 ± 1.2 47.6 ± 6.7 45.7 ± 5.2 (mg/kg/day) 1.0 6.4 ± 0.6 6.1 ± 0.6 8.4 ± I.I 8.1 ± 1.3 46.1 ± 4.3 44.7 ± 5.0 6.3 ± 0.6 5.9 ± 0.6 8.6 ± 1.1 8.2 ± 0.9 43.7 ±58 41.7 ± 4.3 5.0 6.2 ± 0.5 5.8 ± 0.5 7.6 ± 1.2* 7.2 ± 1.1* 43.0 ± 4.9* 41.3 ± 4.8* 6.3 ± 0.8 5.9 ± 0.7 8.4 ± 1.9 7.8 ± 1.7 43.4 ± 5.3 41.0 ± 5.6 these two groups was due to the death of three entire litters (25 pups) in the control group and five entire litters (48 pups) in the 5.0 mg/kg/day dose group, was associated with an increased incidence of weak, thin, or cold pups or pups with no milk in their stomach, and was considered secondary to maternal neglect. Although the survival of pups in the 5.0 mg/kg/day dose group was also lower than the control group, the decrease was due to a greater number (five) of dams that neglected their litters relative to the number of control dams (three). Since the decreased pup survival in the 5.0 mg/kg/ day dose group was due to a limited number of litters and was not a general finding across most litters, the lower pup survival observed at 5.0 mg/kg/day was not statistically significant and was not considered to be treatment-related. Analyses of pup survival, excluding entire litters that were lost due to dam neglect (three in the control, one at 1.0 mg/ kg/day and five at 5.0 mg/kg/day), show that no treatmentrelated effects on F2 pup survival were observed at any dose level (Table 6) .
Gross and histopathology of adults and weanlings. No treatment-related gross pathologic alterations were observed in PI or P2 males or females, or in Fl or F2 weanlings, at any dose level. Histopathologic alterations in the adrenal gland were observed in PI and P2 males and females in the 5.0 mg/kg/day dose group. The histologic alterations were limited to cells of the zona fasciculata and were characterized as very slight to slight vacuolation (consistent with fatty change) in males, and very slight vacuolation and altered tinctorial properties in females.
DISCUSSION
In the present developmental toxicity study, administration of chlorpyrifos to pregnant female rats, by oral gavage, resulted in significant maternal effects that included signs of cholinergic effects, decreased cholinesterase levels, and decreased body weight gain at 15 mg/kg/day and decreased cholinesterase levels at 3.0 mg/kg/day. No maternal effects were observed at 0.1 mg/kg/day. Although maternal toxicity was observed at these two higher dose levels, no developmental effects were observed at any dose level. These results indicate that chlorpyrifos is not selectively toxic to the developing fetuses following oral exposure. The lack of selective toxicity to the fetus observed in this study is supported by the results obtained by other investigators (Ashry et ai, 1994; Stanton et ai, 1994; Chanda et ai, 1993; Deacon et ai, 1980) . In a similarly designed developmental toxicity study, Deacon et al. (1980) gavaged mice with chlorpyrifos at dose levels of 0, 0.1, 1.0, 10 or 25 mg/kg/day. In addition to cholinesterase depression, dose-related maternal effects including decreased growth and/or mortality were observed at 10 and 25 mg/kg/day. Developmental effects of decreased growth and skeletal ossification were observed only at 25 mg/kg/day, a severely maternally toxic dose level. Given the severe toxicity observed in dams given 25 mg/kg/day, the slight effects on fetal growth and development were attributed to the debilitated condition of the dams. When effects on cholinesterase were evaluated, dams showed dose-related decreases at 5*1.0 mg/kg/day while fetal cholinesterase levels were decreased at =510 mg/kg/day. Three additional studies conducted by Ashry et al. (1994) , Stanton et al. (1994), and Chanda et al. (1993) , utilizing high doses (50 to 240 mg/kg) of chlorpyrifos administered by oral gavage or subcutaneous injection, support the differential sensitivity between the dam and the fetus or weanling animal. These authors reported that following chlorpyrifos exposure, fetal and weanling rats were less sensitive to cholinesterase depression (Ashry et al., 1994; Chanda et al., 1993) and/or alterations in neurologic functions (Stanton et al., 1994) than dams. The differential sensitivity between the dam and the fetus is likely to be both exposure and biologically based as Ashry et al. (1994) has reported fetuses showing a delay to maximum total brain acetylcholinesterase inhibition, a decreased level of maximum brain acetylcholinesterase inhibition, and a faster rate of cholinesterase recovery. The rate and magnitude of cholinesterase depression is likely exposure related as the fetal brain represents a deep tissue compartment. The rate of recovery may be biologically related to the rate of enzyme generation/ regeneration. The rapidly growing fetus would be expected to have an increased rate of brain growth, relative to the adult, resulting in an apparent increase in acetylcholinesterase recovery through the diluting of the inhibited enzyme with newly generated brain tissue/ enzyme.
In the present reproduction study, dietary exposure of adult male and female rats to 1.0 and 5.0 mg chlorpyrifos/ kg/day resulted in dose-related parental effects. PI and Fl adult males and females had statistically significant depressed plasma and erythrocyte cholinesterase levels. In addition, both the PI and Fl males and females in the 5.0 mg/kg/day dose group had statistically significant decreases in brain cholinesterase (=s52% of the control values) and histopathologic alteration of the adrenal zona fasciculata. The significant decreases in brain cholinesterase and histopathologic alterations of the adrenal zona fasciculata observed in high-dose males and females were considered to represent parental toxicity. The histopathologic alteration of the adrenal zona fasciculata consisted of very slight to slight vacuolation (consistent with fatty change) in males, and very slight vacuolation and/ or altered tinctorial properties in females. Although the mechanism for the changes in the adrenal have not been determined, it was not attributed directly to cholinesterase inhibition within this organ as the function of the zona fasciculata is controlled by the hypothalamus via the anterior pituitary hormone adrenocorticotrophic hormone. No significant treatment-related parental effects were observed in either generation at 0.1 mg/kg/day. The parental effects observed in this reproduction study were consistent with previously reported effects in Fischer 344 rats. In both subchronic and chronic rat dietary toxicity studies, a NOEL of 0.1 mg/kg/day was established (McCollister et al., 1974; Young et al., 1990) . These earlier studies also found decreased plasma and erythrocyte cholinesterase levels at 1.0 mg/kg/day and decreased plasma, erythrocyte, and brain cholinesterase, and altered histopathology of the adrenal gland at 10 mg/kg/day.
Although parental effects were observed at 1.0 and 5.0 mg/kg/day, no effects on fertility were observed at any dose level and no neonatal effects were observed at 0.1 or 1.0 mg/kg/day in the Fl or F2 litters. The parental toxicity at 5.0 mg/kg/day was accompanied by neonatal effects in the Fl litters. Fl pups from dams given 5.0 mg chlorpyrifos/kg/day had decreased body weight and increased mortality. The neonatal effects observed at 5.0 mg/kg/day in the Fl litters may not have been treatmentrelated as they were not observed in the second generation animals. However, if these neonatal effects were treatment-related, they occurred only at a maternally toxic dose level. It is also important to note that the Fl neonatal females completely recovered their initial preweaning weight reduction, whereas the Fl neonatal males exhibited a near complete recovery (no statistical differences) from their preweaning weight deficit.
The lack of effects on reproductive function and neonatal development observed in this study at dose levels as high as 1.0 mg/kg/day are consistent with the results of a previously conducted three-generation dietary reproduction and developmental toxicity study exposing rats to dose levels of 0, 0.1, 0.3, or 1.0 mg chlorpyrifos/ kg/day (Thompson et al., 1971) . In this earlier study, depressions in parental plasma and erythrocyte cholinesterase were observed without effects on reproductive parameters, fetal development, or neonatal growth, survival, or histopathology, resulting in a reproductive and developmental NOEL of 1.0 mg/kg/day.
In conclusion, the NOELs for the developmental toxicity study were 0.1 mg/kg/day for maternal effects and 15 mg/kg/day for developmental effects. The NOELs for the reproduction study were 0.1 mg/kg/day for parental effects, 1.0 for neonatal effects, and 5 mg/kg/day (highest dose tested) for fertility and reproductive effects. Under the conditions of the studies described herein, oral administration of chlorpyrifos to rats at parentally toxic dose levels was not embryolethal, embryo/fetotoxic, or teratogenic and did not result in adverse effects on fertility or the function of the reproductive organs. These studies, as well as other published studies, also show that chlorpyrifos is not selectively toxic to the embryo, fetus, or neonate. Parentally toxic doses did, however, result in decreased growth and survival in the Fl generation of neonates in the reproduction study. The neonatal effects, however, were of questionable toxicologic significance c Number of females delivering a litter/number of females cohoused with males (percentage). * Number of males which mated resulting in a sperm-positive vagina] smear or pregnant female/number of males cohoused with females (percentage). ' Number of males which sired a litter/number of males resulting in a sperm-positive vaginal smear or pregnant female (percentage). 1 Number of males which sired a litter/number of males cohoused with females (percentage). 1 Number of females delivering a live litter/number of females delivering a litter (percentage). * Percentage of newborn pups that were alive at birth. ' The duration of gestation in days; mean ± SD. ' The number of days the male and female were cohoused prior to mating; mean ± SD. * Mean ± SD. ' Number of live pups on Day 1 or 4/number of pups bom alive (percentage). " Number of pups alive on Day 7, 14, or 21/number of pups alive on Day 4 (percentage). " One male died prior to breeding resulting in 30 females and 29 males.° All litters included in calculation of the index. ' Excluded from the index calculation all litters that died.
